10-Q · May 15, 2026
Alaunos Therapeutics reported no product revenue for the first quarter of 2026, resulting in a net loss of $1.0 million. The company continues to face substantial accumulated deficits of approximately $925.6 million…
Earnings analysis · 10-Q
TCRT earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q excerpt does not include the income statement, balance sheet, cash flow statement, segment data, or MD&A, so revenue, margins, EPS, cash burn, liquidity, and operating trends cannot be quantified from…
Read full summary
The supplied 10-Q excerpt does not include the income statement, balance sheet, cash flow statement, segment data, or MD&A, so revenue, margins, EPS, cash burn, liquidity, and operating trends cannot be quantified from this filing text. The principal developments are an ineffective disclosure-controls conclusion as of June 30, 2026 and a potentially severe Nasdaq listing risk tied to a $5.0 million MVLS threshold and a 30-consecutive-business-day test. The rule is currently stayed following the SEC’s July 29, 2026 notice, but the ultimate outcome and timing remain uncertain.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Nasdaq MVLS Rule Remains Stayed
The Nasdaq MVLS rule remains stayed as of the filing date. The SEC notified Nasdaq on July 29, 2026 that the July 22, 2026 approval order was automatically stayed pending SEC review.
-
No Material Pending Litigation Reported
Management states in Part II, Item 1 that there are no pending litigation matters that, separately or in aggregate, are reasonably likely to have a material adverse effect on the company.
What to watch
-
Potential Nasdaq Delisting
A Nasdaq rule approved on July 22, 2026 would require minimum Market Value of Listed Securities of $5.0 million. If MVLS remains below that threshold for 30 consecutive business days, the company could face immediate suspension and delisting without an automatic cure period.
-
Uncertain SEC Review and Timing
The Nasdaq rule approval has been automatically stayed since July 29, 2026, but the stay is procedural and the company cannot predict the outcome or timing of SEC review, including when Nasdaq might resume measuring the 30-business-day period.
-
Ineffective Disclosure Controls
Management concluded that disclosure controls and procedures were not effective as of June 30, 2026. The filing also states that no changes during the quarter ended June 30, 2026 materially affected, or were reasonably likely to materially affect, internal controls over financial reporting.
Management's outlook
No quantitative revenue or EPS outlook is provided in the supplied 10-Q text; outlook may be addressed separately in the earnings release or call.
Earlier filings 4
10-K · April 30, 2026
Alaunos Therapeutics reported significant challenges in its 10-K filing for the fiscal year ended December 31, 2025, highlighted by a sharp decline in its stockholders' equity to $2,153,000, which is below the Nasdaq…
10-K · March 31, 2026
Alaunos Therapeutics has repositioned from legacy TCR-T cell therapies to an internally developed, preclinical small‑molecule obesity program (lead candidate ALN1003) and reports positive DIO mouse-model…
10-K · March 31, 2025
Alaunos has repositioned as a preclinical small-molecule obesity/metabolic health company centered on ALN1001 while winding down its TCR-T clinical programs. The company initiated in vitro testing in Q4 2024 with…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.